Switch to:
Also traded in: Germany, Mexico

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 0.05
ACT's Cash to Debt is ranked lower than
95% of the 761 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.33 vs. ACT: 0.05 )
Ranked among companies with meaningful Cash to Debt only.
ACT' s Cash to Debt Range Over the Past 10 Years
Min: 0.02  Med: 0.47 Max: 43.62
Current: 0.05
0.02
43.62
Equity to Asset 0.57
ACT's Equity to Asset is ranked lower than
58% of the 704 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. ACT: 0.57 )
Ranked among companies with meaningful Equity to Asset only.
ACT' s Equity to Asset Range Over the Past 10 Years
Min: 0.25  Med: 0.61 Max: 0.93
Current: 0.57
0.25
0.93
F-Score: 6
Z-Score: 1.12
M-Score: -2.47
WACC vs ROIC
7.66%
-1.08%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) -12.34
ACT's Operating margin (%) is ranked lower than
80% of the 707 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.73 vs. ACT: -12.34 )
Ranked among companies with meaningful Operating margin (%) only.
ACT' s Operating margin (%) Range Over the Past 10 Years
Min: -21.33  Med: 6.99 Max: 14.12
Current: -12.34
-21.33
14.12
Net-margin (%) 26.25
ACT's Net-margin (%) is ranked higher than
93% of the 710 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.01 vs. ACT: 26.25 )
Ranked among companies with meaningful Net-margin (%) only.
ACT' s Net-margin (%) Range Over the Past 10 Years
Min: -22.48  Med: 5.41 Max: 25.98
Current: 26.25
-22.48
25.98
ROE (%) 5.87
ACT's ROE (%) is ranked lower than
54% of the 742 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.15 vs. ACT: 5.87 )
Ranked among companies with meaningful ROE (%) only.
ACT' s ROE (%) Range Over the Past 10 Years
Min: -23.54  Med: 6.44 Max: 12.05
Current: 5.87
-23.54
12.05
ROA (%) 3.38
ACT's ROA (%) is ranked lower than
52% of the 766 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.68 vs. ACT: 3.38 )
Ranked among companies with meaningful ROA (%) only.
ACT' s ROA (%) Range Over the Past 10 Years
Min: -13.02  Med: 3.54 Max: 6.67
Current: 3.38
-13.02
6.67
ROC (Joel Greenblatt) (%) -40.04
ACT's ROC (Joel Greenblatt) (%) is ranked lower than
79% of the 759 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.13 vs. ACT: -40.04 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ACT' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -112.05  Med: 20.55 Max: 39.38
Current: -40.04
-112.05
39.38
Revenue Growth (3Y)(%) -3.80
ACT's Revenue Growth (3Y)(%) is ranked lower than
76% of the 601 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.60 vs. ACT: -3.80 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ACT' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -3.8  Med: 17.50 Max: 39.8
Current: -3.8
-3.8
39.8
EBITDA Growth (3Y)(%) 0.80
ACT's EBITDA Growth (3Y)(%) is ranked lower than
65% of the 553 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.40 vs. ACT: 0.80 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ACT' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -3.7  Med: 3.60 Max: 41.1
Current: 0.8
-3.7
41.1
» ACT's 10-Y Financials

Financials (Next Earnings Date: 2016-08-08)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with ACT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Preferred stocks of Allergan PLC

SymbolPriceYieldDescription
AGNPRA899.876.115 1/2 % Cum.Conv.Pref.Shs 2015-1.3.18 Series -A-

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:NYSE:TEVA, OTCPK:TKPYY, NYSE:ZTS, NAS:MYL, OTCPK:ESALY, OTCPK:SGIOF, OTCPK:MKGAY, NYSE:PRGO, OTCPK:APNHY, OTCPK:MTZPY, NYSE:RDY, OTCPK:TAISF, OTCPK:HLUYY, OTCPK:HKMPY, NYSE:VRX, NYSE:MNK, OTCPK:MDABY, NYSE:TARO, OTCPK:SFOSF, NAS:OPK » details
Traded in other countries:A60.Germany, AGN N.Mexico,
Allergan PLC is a specialty pharmaceutical company. The Company is engaged in developing, manufacturing and distributing generic, brand and biosimilar products.

Allergan PLC, formerly known as Actavis PLC was incorporated in Ireland on May 16, 2013. It is an integrated specialty pharmaceutical company. The Company is engaged in development, manufacturing, marketing, sale and distribution of generic, branded generic, brand name, biosimilar and over-the-counter pharmaceutical products. It also develops and out-license generic pharmaceutical products in Europe through its Medis third-party business. It operates in three segments, Pharma, Specialty Brands and Anda Distribution. The Pharma segment includes off-patent pharmaceutical products that are therapeutically equivalent to proprietary products. The Specialty Brands segment includes patent-protected products and certain trademarked off-patent products that the Company sells and markets as brand pharmaceutical products. The Anda Distribution segment distributes generic and brand pharmaceutical products manufactured by third parties, as well as by the Company to independent pharmacies, pharmacy chains, pharmacy buying groups and physicians' offices. It competes with generic manufacturers of pharmaceutical products. It is subject to extensive, complex and evolving regulation by the federal government, the FDA, and to a lesser extent, by the U.S. Drug Enforcement Administration Occupational Safety and Health Administration and state government agencies, as well as by various regulatory agencies in foreign countries where its products or product candidates are being manufactured and/or marketed. The Federal Food, Drug and Cosmetic Act, the Controlled Substances Act and other federal statutes and regulations govern or influence the testing, manufacturing, packing, labeling, storing, record keeping, safety, approval, advertising, promotion, sale and distribution of its products.

Guru Investment Theses on Allergan PLC

Vanguard Health Care Fund Comments on Actavis PLC - Mar 27, 2015

Actavis (ACT) is a specialty pharmaceutical company that develops generic and branded products. We owned Actavis prior to its Forest Labs acquisition but increased our position. We are attracted to the uniqueness of the combined company’s business model, which provides exposure to both generic and branded pharmaceuticals globally. The company’s Irish tax rate could also be strategically important in future mergers and acquisitions. Actavis was the fund’s second-largest holding as of the end of the period.



From Vanguard Health Care Fund (Trades, Portfolio) 2014 Annual Report.



Check out Vanguard Health Care Fund latest stock trades

Bernard Horn Comments on Actavis PLC - Oct 30, 2014

On July 1, Actavis (ACT) announced the completion of its acquisition of Forest Laboratories Inc. (a Fund holding), in a cash and equity transaction valued at approximately $28 billion. We maintained a position in Actavis, as its pro-forma financial statements fit the Polaris valuation profile. As one of the largest generic pharmaceutical companies, Actavis is expected to broaden its product platform with the Forest acquisition, increase operating cash flow and realize $1 billion in cost synergies.

From Bernard Horn (Trades, Portfolio)’s Polaris Global Value Fund Q3 2014 Shareholder Letter.

Check out Bernard Horn latest stock trades

Ratios

vs
industry
vs
history
P/E(ttm) 23.14
ACT's P/E(ttm) is ranked higher than
60% of the 593 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 28.41 vs. ACT: 23.14 )
Ranked among companies with meaningful P/E(ttm) only.
ACT' s P/E(ttm) Range Over the Past 10 Years
Min: 10.94  Med: 26.31 Max: 366.63
Current: 23.14
10.94
366.63
Forward P/E 17.36
ACT's Forward P/E is ranked lower than
56% of the 81 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.39 vs. ACT: 17.36 )
Ranked among companies with meaningful Forward P/E only.
N/A
Price/Owner Earnings (ttm) 43.98
ACT's Price/Owner Earnings (ttm) is ranked lower than
61% of the 282 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 34.57 vs. ACT: 43.98 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
ACT' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 8.13  Med: 19.41 Max: 1279.04
Current: 43.98
8.13
1279.04
P/B 1.36
ACT's P/B is ranked higher than
79% of the 823 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.89 vs. ACT: 1.36 )
Ranked among companies with meaningful P/B only.
ACT' s P/B Range Over the Past 10 Years
Min: 1.03  Med: 1.75 Max: 5.9
Current: 1.36
1.03
5.9
P/S 5.40
ACT's P/S is ranked lower than
69% of the 767 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.74 vs. ACT: 5.40 )
Ranked among companies with meaningful P/S only.
ACT' s P/S Range Over the Past 10 Years
Min: 0.99  Med: 1.84 Max: 17.57
Current: 5.4
0.99
17.57
PFCF 20.54
ACT's PFCF is ranked higher than
52% of the 221 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 21.52 vs. ACT: 20.54 )
Ranked among companies with meaningful PFCF only.
ACT' s PFCF Range Over the Past 10 Years
Min: 6.62  Med: 14.87 Max: 36.71
Current: 20.54
6.62
36.71
POCF 18.38
ACT's POCF is ranked lower than
55% of the 292 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.35 vs. ACT: 18.38 )
Ranked among companies with meaningful POCF only.
ACT' s POCF Range Over the Past 10 Years
Min: 5.97  Med: 12.22 Max: 31.19
Current: 18.38
5.97
31.19
EV-to-EBITDA 31.64
ACT's EV-to-EBITDA is ranked lower than
74% of the 625 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.97 vs. ACT: 31.64 )
Ranked among companies with meaningful EV-to-EBITDA only.
ACT' s EV-to-EBITDA Range Over the Past 10 Years
Min: -224.1  Med: 10.00 Max: 386.1
Current: 31.64
-224.1
386.1
Shiller P/E 1044.73
ACT's Shiller P/E is ranked lower than
99% of the 151 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 50.39 vs. ACT: 1044.73 )
Ranked among companies with meaningful Shiller P/E only.
ACT' s Shiller P/E Range Over the Past 10 Years
Min: 14.77  Med: 50.65 Max: 1507.14
Current: 1044.73
14.77
1507.14
Current Ratio 0.99
ACT's Current Ratio is ranked lower than
89% of the 682 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.39 vs. ACT: 0.99 )
Ranked among companies with meaningful Current Ratio only.
ACT' s Current Ratio Range Over the Past 10 Years
Min: 0.99  Med: 2.89 Max: 9.8
Current: 0.99
0.99
9.8
Quick Ratio 0.89
ACT's Quick Ratio is ranked lower than
80% of the 682 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.78 vs. ACT: 0.89 )
Ranked among companies with meaningful Quick Ratio only.
ACT' s Quick Ratio Range Over the Past 10 Years
Min: 0.78  Med: 1.98 Max: 8.82
Current: 0.89
0.78
8.82
Days Inventory 127.22
ACT's Days Inventory is ranked lower than
58% of the 666 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 114.20 vs. ACT: 127.22 )
Ranked among companies with meaningful Days Inventory only.
ACT' s Days Inventory Range Over the Past 10 Years
Min: 75.66  Med: 119.26 Max: 133.19
Current: 127.22
75.66
133.19
Days Sales Outstanding 54.28
ACT's Days Sales Outstanding is ranked higher than
68% of the 624 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 73.90 vs. ACT: 54.28 )
Ranked among companies with meaningful Days Sales Outstanding only.
ACT' s Days Sales Outstanding Range Over the Past 10 Years
Min: 31.08  Med: 58.63 Max: 92.81
Current: 54.28
31.08
92.81
Days Payable 31.02
ACT's Days Payable is ranked lower than
85% of the 578 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 70.26 vs. ACT: 31.02 )
Ranked among companies with meaningful Days Payable only.
ACT' s Days Payable Range Over the Past 10 Years
Min: 18.72  Med: 59.11 Max: 107.57
Current: 31.02
18.72
107.57

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 1.28
ACT's Price/Projected FCF is ranked higher than
80% of the 344 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.59 vs. ACT: 1.28 )
Ranked among companies with meaningful Price/Projected FCF only.
ACT' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.61  Med: 1.17 Max: 3.29
Current: 1.28
0.61
3.29
Price/Median PS Value 2.94
ACT's Price/Median PS Value is ranked lower than
90% of the 734 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.14 vs. ACT: 2.94 )
Ranked among companies with meaningful Price/Median PS Value only.
ACT' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.67  Med: 1.36 Max: 8.52
Current: 2.94
0.67
8.52
Earnings Yield (Greenblatt) (%) -1.60
ACT's Earnings Yield (Greenblatt) (%) is ranked lower than
73% of the 844 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.90 vs. ACT: -1.60 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ACT' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 1  Med: 6.10 Max: 12.3
Current: -1.6
1
12.3
Forward Rate of Return (Yacktman) (%) 1.91
ACT's Forward Rate of Return (Yacktman) (%) is ranked lower than
61% of the 325 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.60 vs. ACT: 1.91 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
ACT' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -2.4  Med: 7.50 Max: 16.1
Current: 1.91
-2.4
16.1

More Statistics

Short Percentage of Float1.14%
52-Week Range $201.91 - 317.72
Shares Outstanding (Mil)392.44
» More Articles for ACT

Headlines

Articles On GuruFocus.com
Jerome Dodson's Best Investments Jul 27 2016 
Daniel Loeb's Third Point 2nd-Quarter 2016 Investor Letter Jul 27 2016 
Jerome Dodson Comments on Allergan Jul 26 2016 
Jerome Dodson's Parnassus Fund 2nd Quarter Commentary Jul 26 2016 
Weitz Funds Comments on Allergan Jul 20 2016 
Ruane Cunniff Comments on Allergan Jul 13 2016 
Sequoia Fund Addresses Valeant, New Buys, Board Changes in 2nd Quarter Letter Jul 13 2016 
3 of Paul Singer's Top 5 Deals in 1st Quarter Involve Technology Stocks Jun 26 2016 
Steve Mandel Exits Position in Williams Companies in 1st Quarter Jun 24 2016 
'Party Drug' Could Be Johnson & Johnson's Entry Into Antidepressant Market May 22 2016 

More From Other Websites
Allergan (AGN) Stock Is Thursday’s ‘Chart of the Day’ Jul 28 2016
Billionaire Dan Loeb Reiterates Bullish Thesis on Baxter, Holds on to Allergan Stake & Other Market... Jul 28 2016
Teva, Allergan win U.S. antitrust approval for generics deal Jul 27 2016
Teva, Allergan win U.S. antitrust approval for generics deal Jul 27 2016
Teva expect to close $40.5B Allergan generic deal next week Jul 27 2016
Teva expect to close $40.5B Allergan generic deal next week Jul 27 2016
[$$] Teva, Allergan Get FTC Approval for Generics Purchase Jul 27 2016
FTC approves Teva's $40.5B deal for Allergan's generics business Jul 27 2016
Teva purchase of Allergan generics business approved with conditions Jul 27 2016
Jerome Dodson Comments on Allergan Jul 26 2016
Jerome Dodson's Parnassus Fund 2nd Quarter Commentary Jul 26 2016
Allergan Gets Positive Opinion For Its Truberzi For Irritable Bowel Syndrome With Diarrhoea... Jul 25 2016
Credit Suisse says Allergan's drug pipeline is 'underappreciated' Jul 25 2016
Jim Cramer -- I Agree With the Analysts on Gap, Allergan Jul 25 2016
Why Traders Are Watching Tesla, SolarCity, Allergan & Other Stocks Today Jul 25 2016
Specialty Pharma: Earnings Better Be Good…or Else Jul 25 2016
Actual Experience Plc :ACT-GB: Earnings Analysis: For the six months ended March 31, 2016 : July 22,... Jul 22 2016
Amgen (AMGN) Stock Rises on 'Non-Inferior' Late-Stage Trial Results Jul 21 2016
Valeant & Endo: Imagining a World With No Drug Pricing Controversies Jul 21 2016
Weitz Funds Comments on Allergan Jul 20 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)